Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:ONC)

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

PR Newswire 8 days ago

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

PR Newswire April 2, 2024

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

PR Newswire March 7, 2024

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Newsfile March 6, 2024

Oncolytics Biotech to initiate new pancreatic cancer therapy study

Jonathon Brown March 5, 2024

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

PR Newswire March 5, 2024

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

PR Newswire March 4, 2024

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

PR Newswire February 28, 2024

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Newsfile February 15, 2024
View More News ››

Opinion & Analysis (TSX:ONC)

Buzz on the Bullboards: New Year, New Attractive Stocks

Omri Wallach January 9, 2020

Target Price Raised Ninefold on Biotech After Share Consolidation

Streetwise Reports June 6, 2018

Canadian Biotech comes back to life: A buyer's guide

Tony Pullen January 21, 2014
View More Opinion ››

Bullboard Posts (TSX:ONC)

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New shareholder

Woke goofballs the new and the old very funny .
Galaxym31 - 7 hours ago

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New shareholder

Poor little Bucky....you just can't get it, can you....us shareholders don't mind someone with a second opinion.....we just...
Peladawn - 8 hours ago

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New shareholder

The forever pumpers just can't stand someone with a different opinion. I guess they like a dictator form of rule. Reminds me of the...
Buckhenry - 8 hours ago

RE:RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway

April 18, 2024 - AACR2024 reports that biotech has emerged from a "nuclear winter" in biotech which lasted 2 years and affected...
Noteable - 10 hours ago

RE:RE:CAR-T update

This is BIG it would seem!
CMHarring218431 - 10 hours ago

RE:RE:CAR-T update

https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following...
Noteable - 10 hours ago
View more Bullboard ››

Forsys Metals Corp

Forsys Metals Corp

Forsys Metals Corp. is a Canada-based company, which is engaged in the business of acquiring, exploring and developing ...
View More »